Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.53 |
| ▸ | MDM4 | O15151 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 4/20 | 0.51 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401108 | 1.00 | KMT2A (0.56) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL4600663 | 1.00 | KMT2A (0.56) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29401342 | 1.00 | KMT2A (0.56) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29569815 | 0.97 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL13401519 | 0.97 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL25356641 | 0.97 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29362229 | 0.97 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL31647336 | 0.97 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL119468 | 0.97 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29850382 | 0.97 | KMT2A (0.55) | KMT2AMDM2MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-11149066-B2 | Thrombospondin 1-binding peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-10-19 | — | — | US | disclosed |
| US-20200131230-A1 | THROMBOSPONDIN 1-BINDING PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149066-B2 | Thrombospondin 1-binding peptide | SERPINC1, TEK, ARGLU1 | KMT2A 4374/4885MDM2 4184/4885MDM4 3675/4885 |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | KMT2A 3406/4885MDM2 3730/4885MDM4 934/4885 |
| US-20200131230-A1 | THROMBOSPONDIN 1-BINDING PEPTIDE | SERPINC1, TEK, ARGLU1 | KMT2A 4374/4885MDM2 4184/4885MDM4 3675/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | KMT2A 1805/4885MDM2 2451/4885MDM4 963/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | KMT2A 3083/4885MDM2 423/4885MDM4 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.